Biological response modifiers: Current use and future prospects in cancer therapy

Indian Journal of Cancer

Volumn 47, Issue 4, 2010, Pages 443-451

  Bisht, M ^a   Bist, S S ^b   Dhasmana, D C ^a  

^a HIMALAYAN INSTITUTE HOSPITAL TRUST   (India)

^b HIMALAYAN INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Biological response modifiers; cancer; monoclonal antibodies

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; BEVACIZUMAB; BIOLOGICAL RESPONSE MODIFIER; BORTEZOMIB; CETUXIMAB; DEXAMETHASONE; EDRECOLOMAB; EPRATUZUMAB; ERLOTINIB; GEFITINIB; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; LESTAURTINIB; NILOTINIB; PANITUMUMAB; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; RECOMBINANT INTERLEUKIN 2; RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RECOMBINANT THROMBOPOIETIN; RITUXIMAB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; TOSITUMOMAB; TRASTUZUMAB; VATALANIB; VIRUS VACCINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; AMELANOTIC MELANOMA; ANASARCA; ANGIOGENESIS; ANOREXIA; ANTIGEN EXPRESSION; ASCITES; B CELL LYMPHOMA; BREAST CANCER; CANCER CELL DESTRUCTION; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CARCINOID SYNDROME; CARDIOMYOPATHY; CELL PROLIFERATION; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; COMA; CONFUSION; CUTANEOUS T CELL LYMPHOMA; DRUG ACTIVITY; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HAIRY CELL LEUKEMIA; HEAD AND NECK CANCER; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; IMMUNE RESPONSE; INTERSTITIAL NEPHRITIS; KAPOSI SARCOMA; KIDNEY CARCINOMA; KIDNEY METASTASIS; LUNG EDEMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTE DEPLETION; MANTLE CELL LYMPHOMA; MELANOMA; METASTASIS; MULTIPLE MYELOMA; MYALGIA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NAUSEA; NEOPLASM; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PANCYTOPENIA; PROSTATE CANCER; RECTUM CANCER; REVIEW; SIDE EFFECT; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; T CELL DEPLETION; T CELL LYMPHOMA; THROMBOCYTOPENIA; TUMOR DIFFERENTIATION; UTERINE CERVIX CANCER; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; NEOPLASMS;

EID: 78650077527     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.73559     Document Type: Review

References (46)

1. National cancer institute. NCI drug dictionary (document on internet). USA: The organization. Available from: http://www.cancer.gov/drugdictionary/ [last cited on 2009 Nov 1]. [last updated on 2010 Mar 4].
2. Quillin P. Nutrients as biological response modifiers. Available from: http://www.patrickquillin.com/tip-season.htmlangio.org/ua.php [Last cited on 2009 Dec 8].
3. Oettgen HF, Old LJ. The history of cancer immunotherapy. Biologic therapy of cancer. In: De Vita VT Jr, Hellman S, Rossenberg SA, editors. Philadelphia: Lippincott; 1991. p. 81-101.
4. Einhorn S, Strander H. Interferon treatment of human malignancies-a short review. Med Oncol Tumor Pharmacother 1993;10:25-9.
5. Steiner A, Wolf C, Pehamberger H. Comparison of the effects of three different treatment regimens of recombinant interferons (r-IFN a, r-IFN g, and r-IFN a +cimetidine) in disseminated malignant melanoma. J Cancer Res Clin Oncol 1987;113:459-65.
6. Tompkins WA. Immunomodulation and therapeutic effects of the oral use of interferon a: Mechanism of action. J Interferon Cytokine Res 1999;19:817-28.
7. Safrin S. Antiviral agents. Basic and clinical pharmacology. In: Katzung BG, editor. New York: McGraw Hill; 2000. p. 823-44.
8. Lotze MT, Grimm EA, Mazumdar A, Strausser JL, Rosenberg SA. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res 1981;41:4420-5.
9. Rosenberg SA, Lotze MT, Yang JC, Absersold PM, Linehan WM, Seipp CA, et al. Experience with the use of high dose interleukin-2 in the treatment of 625 cancer patients. Ann Surg 1989;210:474-84.
10. Lake DF, Akporiaye ET, Hersh EM. Immunopharmacology. Basic and clinical pharmacology. In: Katzung BG, editor. New York: McGraw Hill; 2001. p. 959-86.
11. Cortes JE, Kantarjian HM, O'Brien S, Giles F, Keating MJ, Freireich EJ, et al. A pilot study of interleukin-2 for Adult patients with acute myelogenous leukemia in first complete remission. Cancer 1999;85:1506-13.
12. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high dose bolus interleukin-2. JAMA 1994;271:907-13.
13. Legha SS, Gianan MA, Plager C, Eton OE, Papadopoulous NE. Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. Cancer 1996;77:89-96.
14. Legha SS, Buzaid AC. Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in treatment of advanced melanoma. Semin Oncol 1993;20:27-32.
15. van Zaanen HC, Koopmans RP, Aarden LA, Rensink HJ, Stouthard JM, Warnaar SO, et al. Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. J Clin Invest 1996;98:1441-8.
16. Oppenheim JJ, Murphy WJ, Chertox O, Schirrmacher V, Wang JM. Prospects for cytokine and chemokine biotherapy. Clin Cancer Res 1997;3:2682-6.
17. Chabner BA, Amrein PC, Druker BJ, Michaelson MD, Mitsiades CS, Gross PE, et al. Antineoplastic agents. 11 th ed. Goodman Gilman's: The pharmacological basis of therapeutics. In: Brunton LL editor. New York: McGraw hill (USA); 2006. p.1315-403.
18. Gupta N, Srivastava A. Monoclonal antibodies: Targeted therapy. Indian J Pharmacol 2006;38:390-6.
19. Crosier PS, Clark SC. Basic biology of the hematopoietic growth factors. Semin Oncol 1992;19:349-61.
20. Dreke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-84.
21. Kaushansky K. Thrombopoietin. N Engl J Med 1998;339:746-54.
22. Nijsten TE, Stern RS. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: A nested cohort study. J Am Acad Dermatol 2003;49:644-50.
23. Zhang C, Duvic M. Retinoids: Therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma. Dermatol Ther 2003;16:322-30.
24. Hubbard SR, Till JH. Protein tyrosine kinase structure and function. Annu Rev Biochem 2000;69:373-98.
25. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411:355-65.
26. Chu E, Sartorelli AC. Cancer chemotherapy. 9th ed. Basic and Clinical Pharmacology. In: Katzung BG, editor. New York: McGraw Hill; 2004. p. 898-930.
27. Cohem MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: Gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003;8:303-6.
28. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or Carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
29. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
30. Li Z, Xu M, Xing S, Ho WT, Ishii T, Li Q, Fu X, Zhao Z. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem 2007;282:3428-32.
31. Ozols RF, Herbst RS, Colson YL, Gralow J, Bonner J, Curran WJ Jr, et al. Clinical Cancer Advances 2006: Major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology. J Clin Oncol 2007;25:146-62.
32. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542-51.
33. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
34. Blankenstein T, Qin ZH, Uberla K, Muller W, Rosen H, Volk HD, et al. Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J Exp Med 1991;173:1047-52.
35. Grnhagen DJ, de Wilt JH, ten Hagen TL, Eggermont AM. Technology Insight: Utility of TNF-Alpha-based isolated limb perfusion to avoid amputation for irresectable tumors of the extremities. Nat Clin Pract Oncol 2006;3:94-103.
36. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications. Leukemia 2001;15:1950-61.
37. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-6.
38. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications. Blood 2002;99:4525-30.
39. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-50.
40. Rini BI. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: Current status and future directions. Clin Cancer Res 2007;13:1098-106.
41. The angiogenesis foundation. Understanding angiogenesis (document on the internet) Cambridge: The organization; 1994. Available from: http://www.angio.org/ua.php [last cited on 2009 July 12]. [last updated on 2009 Jul 10].
42. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow up from a randomized control trial. Lancet 2006;367:1247-55.
43. Pardoll DM. Cancer vaccines. Nat Med 1998;4:525-31.
44. Cancer topics (document on the internet). Available from: http://www.cancer.gov/cancertopics/factsheet/cancervaccine [last cited 2009 Oct 12]. [last updated on 2006 Aug 6].
45. Pardoll DM. Therapeutic vaccination for cancer. Clin Immunol 2000;95:S44-62.
46. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000;191:423-34.